|Bid||21.92 x 1100|
|Ask||22.40 x 800|
|Day's Range||20.77 - 22.09|
|52 Week Range||9.87 - 32.74|
|Beta (3Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.09|
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
There are dozens of listed biotech and pharmaceutical companies with scant revenues that have managed to carry out public offerings to raise funding purely for research. MacroGenics Inc. (MGNX) is a classic example of one such company. With the recent spike in its stock price, and its upcoming offering, the stock is an excellent subject of analysis.
ROCKVILLE, MD, Feb. 13, 2019 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions. In addition, MacroGenics has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions. MacroGenics anticipates the total gross proceeds from the offering (before deducting underwriters’ discounts and commissions and estimated offering expenses) will be approximately $110 million, excluding any exercise of the underwriters’ option to purchase additional shares.
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has commenced an underwritten public offering of shares of its common stock pursuant to its existing shelf registration statement. MacroGenics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. The shares are being offered by MacroGenics pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC).
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
Positive trial results for a cancer drug boost shares by 130% in one day. Time for newer investors in the stock to take chips off the table?
MacroGenics Rose 130.42% on February 6Share price movements On February 6, MacroGenics (MGNX) closed at $25.60, which is 130.42% higher than the previous closing price, 159.37% higher than its 52-week low of $9.87, and 21.81% below its 52-week high
The successful late-stage trial is a big victory for the Rockville biotech, which focuses on antibody-based therapeutics to treat cancer.
Nomura sees the stock between $19 and $28 on positive Sophia results, Bloomberg says. Nomera and Leerink played lead roles in MacroGenics' public offering of 4,500,000 common shares priced at $21.25 in March 2018.
Macrogenics stock rocketed by triple digits Wednesday after the firm said its breast cancer treatment outperformed Roche's competing drug, the blockbuster Herceptin, in a late-stage study.
A biotechnology sector-specific exchange traded fund specialized in tracking immunotherapy drugmakers bucked the broader market trends and surged Wednesday after MacroGenics (NasdaqGS: MGNX) announced ...
The latest big move in a volatile year for MacroGenics highlights the outsize risks and potential benefits of investing in clinical-stage biotech startups.
Premier Health Group (OTC:PHGRF) (CSE:PHGI), Pulmatrix Inc (PULM), MacroGenics Inc (MGNX), and Proteostasis Therapeutics Inc (PTI) represent four biotech companies creating nuanced approaches to further the advancement of modern medicine. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments which demonstrate Premier's dedication to the betterment of the biotech industry, and more importantly, to consumers looking to enhance their quality of life. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced at the tail-end of last month that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
Shares of biotech MacroGenics Inc. shot up 110% in premarket trade Wednesday after the company announced that the Phase 3 trial of potential breast cancer treatment margetuximab met its primary endpoint. Margetuximab is the company's monoclonal antibody aimed at treating later-stage breast cancer patients who test positive for a protein called human epidermal growth factor receptor 2, or HER-2. A gene mutation that makes an excess of the HER-2 protein is present in about 15% of primary invasive breast cancers, according to UpToDate, an evidence-based medical resource used by clinicians. This particular trial showed longer progression-free survival in patients treated with a combination of margetuximab and chemotherapy compared to those on trastuzumab (brand name Herceptin) and chemotherapy, a standard-of-care treatment. The company also said approximately 85% of patients in the study were carriers of the CD16A 158F allele, a gene variation has been associated with a reduced clinical response to Herceptin and other antibodies. MacroGenics said it plans to submit a biologics license application to the U.S. Food and Drug Administration in the second half of 2019. Shares of MacroGenics have fallen 13% in the year to date, while the S&P 500 has gained 9.2%.
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced positive results from SOPHIA, the Company’s Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. Margetuximab is an investigational immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc Optimization technology platform.
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.
On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.